Health Affairs, 24, no. 2 (2005): 483-490 doi: 10.1377/hlthaff.24.2.483 © 2005 by Project HOPE	New Online   New Issue: China & India   Obesity In China   Pay Cuts For Medicare Docs   Access To Care Woes

This Article Full Text (HTML) Reprint (PDF) Submit a response to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services E-mail this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Archive Download to Citation Manager Reprints & Permissions Citing Articles Citing Articles via ISI Web of Science (9) Citing Articles via Google Scholar Google Scholar Articles by Zick, C. D. Articles by Green, R. C. Search for Related Content PubMed PubMed Citation Articles by Zick, C. D. Articles by Green, R. C. Related Collections Insurance Market Business Of Health Chronic Care Consumer Issues Elderly Ethical Issues Insurance Coverage Legal/Regulatory Issues Long-Term Care Research And Technology

Health Tracking

MARKETWATCH

Genetic Testing For Alzheimer’s Disease And Its Impact On Insurance Purchasing Behavior

New genetic tests for adult-onset diseases raise concerns about possible adverse selection in insurance markets. To test for this behavior, we followed 148 cognitively normal people participating in a randomized clinical trial of genetic testing for Alzheimer’s disease for one year after risk assessment and Apolipoprotein E (APOE) genotype disclosure. Although no significant differences were found in health, life, or disability insurance purchases, those who tested positive were 5.76 times more likely to have altered their long-term care insurance than those who did not receive APOE genotype disclosure. If genetic testing for Alzheimer’s risk assessment becomes common, it could trigger adverse selection in long-term care insurance.

                      What's this?